APAC Foot and Ankle Allograft Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS 1 INTRODUCTION 32 1.1 OBJECTIVES OF THE STUDY 32 1.2 MARKET DEFINITION 32 1.3 OVERVIEW OF ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET 32 1.4 LIMITATIONS 34 1.5 MARKETS COVERED 34 2 MARKET SEGMENTATION 37 2.1 MARKETS COVERED 37 2.2 GEOGRAPHICAL SCOPE 38 2.3 YEARS CONSIDERED FOR THE STUDY 39 2.4 CURRENCY AND PRICING 39 2.5 DBMR TRIPOD DATA VALIDATION MODEL 40 2.6 MULTIVARIATE MODELLING 43 2.7 END USER LIFELINE CURVE 43 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44 2.9 DBMR MARKET POSITION GRID 45 2.10 MARKET APPLICATION COVERAGE GRID 46 2.11 VENDOR SHARE ANALYSIS 47 2.12 SECONDARY SOURCES 48 2.13 ASSUMPTIONS 48 3 EXECUTIVE SUMMARY 49 4 PREMIUM INSIGHTS 51 4.1 PORTERS FIVE FORCES 52 5 INDUSTRIAL INSIGHTS: 53 5.1 CONCLUSION: 53 6 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET: REGULATIONS 54 6.1 U.S. 55 6.2 CANADA 56 6.3 EUROPE 56 7 MARKET OVERVIEW 58 7.1 DRIVERS 60 7.1.1 GROWING GERIATRIC POPULATION 60 7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 60 7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 61 7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 62 7.2 RESTRAINTS 63 7.2.1 STRINGENT REGULATORY 63 7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 63 7.3 OPPORTUNITIES 64 7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 64 7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 65 7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 66 7.4 CHALLENGES 67 7.4.1 COVID-19 IMPACT ON ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET 67 7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 68 7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 69 8 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 70 8.1 OVERVIEW 71 8.2 ALLOGRAFT WEDGES 74 8.3 ALLOGRAFT TENDONS 74 8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 75 8.5 CARTILAGE ALLOGRAFT MATRIX 76 8.6 SKIN ALLOGRAFTS 77 8.7 AMNIOTIC MEMBRANES 78 9 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 79 9.1 OVERVIEW 80 9.2 ORTHOPEDIC RECONSTRUCTION 83 9.2.1 NON-UNIONS FRACTURES 84 9.2.2 ARTHRODESIS PROCEDURES 84 9.2.3 OSTEOTOMY PROCEDURES 84 9.3 CARTILAGE RESTORATION 84 9.3.1 TALAR DOME REPAIR 85 9.3.2 TIBIAL PLAFOND REPAIR 85 9.3.3 METATARSAL REPAIR 85 9.3.4 TALONAVICULAR JOINT REPAIR 85 9.3.5 SUBTALAR JOINT REPAIR 85 9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 85 9.4.1 TENDON AUGMENTATION 86 9.4.2 LIGAMENT REPAIR 86 9.4.3 FAT PAD REPLACEMENT 86 9.4.4 PLANTAR PLATE REPAIR 87 9.5 WOUND CARE 87 9.5.1 ANKLE ULCER TREATMENT 88 9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 88 10 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 89 10.1 OVERVIEW 90 10.2 MIDFOOT PROCEDURES 93 10.2.1 CUBOID FRACTURE 94 10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 94 10.2.3 MEDIAL COLUMN ARTHRODESIS 94 10.2.4 LISFRANC 94 10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 94 10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 94 10.2.7 NAVICULAR FRACTURE 94 10.2.8 OTHER MIDFOOT PROCEDURES 94 10.3 HIND-FOOT PROCEDURES 94 10.3.1 CALCANEAL FRACTURE 95 10.3.2 LATERAL COLUMN LENGTHENING 95 10.3.3 TALONAVICULAR JOINT ARTHRODESIS 96 10.3.4 TRIPLE ARTHRODESIS 96 10.3.5 OTHER HINDFOOT PROCEDURES 96 11 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 97 11.1 OVERVIEW 98 11.2 HOSPITALS 101 11.3 ORTHOPEDIC CLINICS 101 11.4 AMBULATORY SURGICAL CENTERS 102 11.5 ACADEMIC AND RESEARCH INSTITUTES 103 11.6 OTHER END USERS 104 12 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 105 12.1 ASIA-PACIFIC 106 12.1.1 CHINA 114 12.1.2 INDIA 117 12.1.3 JAPAN 120 12.1.4 AUSTRALIA 123 12.1.5 SOUTH KOREA 126 12.1.6 SINGAPORE 129 12.1.7 INDONESIA 132 12.1.8 THAILAND 135 12.1.9 MALAYSIA 138 12.1.10 PHILIPPINES 141 12.1.11 REST OF ASIA-PACIFIC 144 13 ASIA PACIFIC FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 145 13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 145 14 SWOT ANALYSIS 146 15 COMPANY PROFILE 147 15.1 LIFENET HEALTH 147 15.1.1 COMPANY SNAPSHOT 147 15.1.2 COMPANY SHARE ANALYSIS 147 15.1.3 PRODUCT PORTFOLIO 148 15.1.4 RECENT DEVELOPMENTS 149 15.1.4.1 CONFERENCE 149 15.1.4.2 PRODUCT LAUNCH 150 15.2 ZIMMER BIOMET 151 15.2.1 COMPANY SNAPSHOT 151 15.2.2 REVENUE ANALYSIS 151 15.2.3 COMPANY SHARE ANALYSIS 152 15.2.4 PRODUCT PORTFOLIO 152 15.2.5 RECENT DEVELOPMENT 152 15.2.5.1 PARTNERSHIP 152 15.3 JOHNSON & JOHNSON SERVICES, INC. 153 15.3.1 COMPANY SNAPSHOT 153 15.3.2 REVENUE ANALYSIS 153 15.3.3 COMPANY SHARE ANALYSIS 154 15.3.4 PRODUCT PORTFOLIO 154 15.3.5 RECENT DEVELOPMENTS 154 15.3.5.1 EVENT 154 15.3.5.2 PRODUCT LAUNCH 154 15.4 INTEGRA LIFESCIENCES 155 15.4.1 COMPANY SNAPSHOT 155 15.4.2 REVENUE ANALYSIS 155 15.4.3 COMPANY SHARE ANALYSIS 156 15.4.4 PRODUCT PORTFOLIO 156 15.4.5 RECENT DEVELOPMENTS 156 15.4.5.1 POSITIVE CLINICAL OUTCOME 156 15.4.5.2 AGREEMENT 156 15.4.5.3 ACQUISITION 157 15.5 CONMED CORPORATION (2022) 158 15.5.1 COMPANY SNAPSHOT 158 15.5.2 REVENUE ANALYSIS 158 15.5.3 COMPANY SHARE ANALYSIS 159 15.5.4 PRODUCT PORTFOLIO 159 15.5.5 RECENT DEVELOPMENT 160 15.5.5.1 ACQUISITION 160 15.6 ALLOSOURCE 161 15.6.1 COMPANY SNAPSHOT 161 15.6.2 PRODUCT PORTFOLIO 161 15.6.3 RECENT DEVELOPMENT 162 15.6.3.1 PRODUCT LAUNCH 162 15.7 ALON SOURCE GROUP 163 15.7.1 COMPANY SNAPSHOT 163 15.7.2 PRODUCT PORTFOLIO 163 15.7.3 RECENT DEVELOPMENT 163 15.8 AMNIOX MEDICAL INC. 164 15.8.1 COMPANY SNAPSHOT 164 15.8.2 PRODUCT PORTFOLIO 164 15.8.3 RECENT DEVELOPMENT 164 15.8.3.1 PARTNERSHIP 164 15.9 ARTHREX 165 15.9.1 COMPANY SNAPSHOT 165 15.9.2 PRODUCT PORTFOLIO 165 15.9.3 RECENT DEVELOPMENT 165 15.9.3.1 PRODUCT LAUNCH 165 15.10 BIOVENTUS 166 15.10.1 COMPANY SNAPSHOT 166 15.10.2 REVENUE ANALYSIS 166 15.10.3 PRODUCT PORTFOLIO 167 15.10.4 RECENT DEVELOPMENT 167 15.10.4.1 CO-DEVELOPMENT 167 15.11 BONE BANK ALLOGRAFTS 168 15.11.1 COMPANY SNAPSHOT 168 15.11.2 PRODUCT PORTFOLIO 168 15.11.3 RECENT DEVELOPMENTS 168 15.11.3.1 PARTNERSHIP 168 15.12 GLOBUS MEDICAL 169 15.12.1 COMPANY SNAPSHOT 169 15.12.2 REVENUE ANALYSIS 169 15.12.3 PRODUCT PORTFOLIO 170 15.12.4 RECENT DEVELOPMENTS 170 15.12.4.1 M&A 170 15.13 INSTITUT STRAUMANN 171 15.13.1 COMPANY SNAPSHOT 171 15.13.2 REVENUE ANALYSIS 171 15.13.3 PRODUCT PORTFOLIO 172 15.13.4 RECENT DEVELOPMENT 172 15.14 JRF ORTHO 173 15.14.1 COMPANY SNAPSHOT 173 15.14.2 PRODUCT PORTFOLIO 173 15.14.3 RECENT DEVELOPMENT 174 15.14.3.1 PARTNERSHIP 174 15.15 NVISION BIOMEDICAL TECHNOLOGIES. 175 15.15.1 COMPANY SNAPSHOT 175 15.15.2 PRODUCT PORTFOLIO 175 15.15.3 RECENT DEVELOPMENT 175 15.15.3.1 ACQUISITION 175 15.16 PARAGON28, INC. 176 15.16.1 COMPANY SNAPSHOT 176 15.16.2 REVENUE ANALYSIS 176 15.16.3 PRODUCT PORTFOLIO 177 15.16.4 RECENT DEVELOPMENT 177 15.16.4.1 ACQUISITION 177 15.17 ORGANOGENESIS INC 178 15.17.1 COMPANY SNAPSHOT 178 15.17.2 REVENUE ANALYSIS 178 15.17.3 PRODUCT PORTFOLIO 179 15.17.4 RECENT DEVELOPMENTS 179 15.17.4.1 CONFERENCE 179 15.17.4.2 ACQUISITION 179 15.18 SMITH + NEPHEW 180 15.18.1 COMPANY SNAPSHOT 180 15.18.2 REVENUE ANALYSIS 180 15.18.3 PRODUCT PORTFOLIO 181 15.18.4 RECENT DEVELOPMENTS 181 15.18.4.1 EVENT 181 15.18.4.2 ACQUISITION 181 15.19 STRYKER 182 15.19.1 COMPANY SNAPSHOT 182 15.19.2 REVENUE ANALYSIS 182 15.19.3 PRODUCT PORTFOLIO 183 15.19.4 RECENT DEVELOPMENT 183 16 QUESTIONNAIRE 184 17 RELATED REPORTS 187